Why Pharmx Technologies (ASX:PHX) Shares Are Falling Today

Sonal Goyal

20 October 2026 09:18 PM AEDT

Why Pharmx Technologies (ASX:PHX) Shares Are Falling Today

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

Pharmx Technologies Ltd (ASX:PHX) touched a 52-week low during the 20 October 2026 session and closed at $0.07, down 11.39%.
Pharmx said on 7 October 2026 that it would release a Business update on 12 October and host an analyst briefing on 14 October.
The announcement did not contain financial results; those were scheduled for the business update that followed.

Pharmx Technologies Ltd (ASX:PHX) touched a 52-week low during the Trading session on 20 October 2026 and closed at $0.07, down 11.39%. Pharmx’s latest announcement covered here was released on 7 October 2026 and said it would release a Q1 FY27 business update on 12 October 2026. No latest announcement has driven the share price move, so the announcement is described below on its own terms.

About Pharmx Technologies

Pharmx Technologies Limited (ASX:PHX) is an ASX-listed company that reports on a financial year with first-quarter updates, and it releases business updates alongside analyst briefings. The announcement reviewed here does not describe its products, so its business is not detailed in this article beyond its listing.

The Q1 FY27 update notice

On 7 October 2026 Pharmx announced that it would release its business update for the first quarter of FY27 on Monday 12 October 2026. To discuss the update in more detail, an analyst briefing in the form of a webinar was scheduled for 11:30am AEST on Wednesday 14 October 2026, with a registration link provided.

The announcement was authorised for lodgement by the chief executive. It contained no revenue, profit, cash or operating figures, so the notice itself provides no information on the company’s performance during the quarter.

What the notice does and does not cover

The notice is a scheduling announcement. The business update on 12 October 2026 and the analyst briefing on 14 October 2026 were the occasions on which the company planned to give its results and commentary, and those documents were not part of the material reviewed for this article.

The share price move is therefore not described by reference to any financial result in the notice.

Sector backdrop

Small listed companies often release quarterly business updates and hold analyst webinars to explain their trading, in addition to formal periodic reports. For investors in this part of the market, the contents of those updates, such as Revenue and cash balances, are typically the main sources of information between half-year and annual reports.

Healthcare and pharmacy-related technology companies depend on customer adoption, regulation and funding to scale.

Risks shareholders should weigh

The notice has no financial information, and without the business update an assessment of the company’s trading is not possible from this announcement. The share price has fallen to a 52-week low.

Small companies with limited public information can see large moves in their share prices, and the figures in the later business update would determine how the market views the company.

What’s next

Items to watch include the details in the Q1 FY27 business update and any recording or transcript of the 14 October analyst webinar, the company’s next quarterly Cash Flow report and any further announcements on trading.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.